AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: TKi can also abrogate the activation of PI3K/Akt/mTOR, and therefore in the TKi-resistant cells, simultaneous inhibition of PI3K and Akt/mTOR is recommended to obtain a potent pro-apoptotic effect in CML cells.